Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
---|
04/01/2004 | US20040063634 Modified kertinocyte growth factor (kgf) with reduced immunogenicity |
04/01/2004 | US20040063628 Active agent delivery systems and methods for protecting and administering active agents |
04/01/2004 | US20040063615 For therapy of diabetes |
04/01/2004 | US20040063611 Comprising levothyroxine sodium, gelatine and fillers, which is free of organic solvent residues |
04/01/2004 | US20040063187 Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of chromatography |
04/01/2004 | US20040063140 Methods for diagnosis of cancer using erbB-3 |
04/01/2004 | US20040062855 Edible PGA coating composition |
04/01/2004 | US20040062843 Molecular press dehydration method for vegetative tissue using the solid phase of water soluble polymer substances as a dehydrating agent |
04/01/2004 | US20040062813 Transdermal drug delivery devices having coated microprotrusions |
04/01/2004 | US20040062812 Drug in mixture of matrix forming polymer and ion exchange resin |
04/01/2004 | US20040062810 Removal blockage in blood vessels; mixture of angiogenesis inhibitor and polymer |
04/01/2004 | US20040062808 Agent delivery system capable of selectively releasing an agent |
04/01/2004 | US20040062805 Pregelatinized starch in a controlled release formulation |
04/01/2004 | US20040062804 Multilayer; active materials, core, shell |
04/01/2004 | US20040062800 Compressed matrix tablet; mixture of drug and swellable polymer; side effect reduction |
04/01/2004 | US20040062796 Enteric administering; anticancer, antiulcer agents; drug with bioadhesive ligand |
04/01/2004 | US20040062793 Protein network; wound healing agent |
04/01/2004 | US20040062779 Fine particle sizes; mixture of ascoric acid in stabilization, anhydrous vehicle; transdermal penetration |
04/01/2004 | US20040062773 Compositions for the delivery of antigens |
04/01/2004 | US20040062761 Nucleic acid and corresponding protein entitled 151P3D4 useful in treatment and detection of cancer |
04/01/2004 | US20040062749 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity |
04/01/2004 | US20040062748 Complex of active material and polyoxyethylene glycol |
04/01/2004 | US20040062746 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
04/01/2004 | US20040062743 Mixture with film forming polymer |
04/01/2004 | US20040062733 Subunguicide, and method for treating onychomycosis |
04/01/2004 | US20040062724 Thin, flexible, multilayer film; applying, adhesion to teeth; supplying active materials |
04/01/2004 | US20040062719 Carrier for drug delivery; crystal structure core with surface coating; induce crystallization of amorphous particles; hermetic sealed packages |
04/01/2004 | US20040062718 Particles for inhalation having sustained release properties |
04/01/2004 | DE10244657A1 Improving flowability of body fluids, e.g. lymph or blood, comprises introduction of defoamer such as polydimethyl siloxane, useful, e.g. in promoting removal of bacterial degradation products |
04/01/2004 | DE10244282A1 Zubereitung mit antioxidanten Eigenschaften Composition having antioxidant properties |
04/01/2004 | DE10243365A1 Composition containing propoxylated and ethoxylated alkanol, useful as surfactant in e.g. cleaning compositions and pharmaceuticals, has low free alcohol content |
04/01/2004 | CA2535769A1 Polymer-linker-drug conjugates for targeted drug delivery |
04/01/2004 | CA2499900A1 Dri nasal sprays |
04/01/2004 | CA2499681A1 Drug delivery |
04/01/2004 | CA2499321A1 Obtaining and use of therapeutic antibodies entering into the cell |
04/01/2004 | CA2499093A1 Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer. |
04/01/2004 | CA2498331A1 Formulation for lipophilic agents |
04/01/2004 | CA2443463A1 Concentrate of a factor viii:c-containing von willebrand factor and the process relating thereto |
03/31/2004 | EP1402913A1 Dry powder inhalation system for transpulmonary administration |
03/31/2004 | EP1402903A1 Method of transporting physiological polymer using protein having rxp repeated sequence |
03/31/2004 | EP1402901A1 Test kit for intracellular introduction of protein and/or peptide and method of intracellular introduction |
03/31/2004 | EP1402897A2 Novel indications of Mannan-binding lectin (MBL) in the treatment of immunocompromised individuals |
03/31/2004 | EP1402884A1 Liposome-containing remedy for the treatment of vascular diseases |
03/31/2004 | EP1402882A1 Acid-containing tooth desensitising material |
03/31/2004 | EP1402786A1 Ximenynic acid |
03/31/2004 | EP1402256A2 P-cadherin as a target for anti-cancer therapy |
03/31/2004 | EP1402039A1 MUTANT FORMS OF EtxB AND CtxB AND THEIR USE AS CARRIERS |
03/31/2004 | EP1402015A2 A soluble complex comprising a retroviral surface glycoprotein |
03/31/2004 | EP1401918A2 Biodegradable poly(beta-amino esters) and uses thereof |
03/31/2004 | EP1401875A1 Hyaluronic acid containing bioconjugates : targeted delivery of anti-cancer drugs to cancer cells |
03/31/2004 | EP1401818A2 Targeted multivalent macromolecules |
03/31/2004 | EP1401567A1 Unimolecular polymeric micelles with an ionizable inner core |
03/31/2004 | EP1401504A1 Uv-screening peptide-flavonoid conjugates |
03/31/2004 | EP1401503A1 Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
03/31/2004 | EP1401502A1 Pharmaceutical formulation |
03/31/2004 | EP1401501A1 Oral pharmaceutical compositions with modified release of the active ingredient |
03/31/2004 | EP1401500A1 Nucleotide compounds that block the bitter taste of oral compositions |
03/31/2004 | EP1401480A2 Use of endostatin in the treatment of ocular neovascularization |
03/31/2004 | EP1401479A2 Detection and therapy of vulnerable plaque with photodynamic compounds |
03/31/2004 | EP1401473A2 Transporters comprising spaced arginine moieties |
03/31/2004 | EP1401467A1 Alpha-fetoprotein peptides and uses thereof |
03/31/2004 | EP1401466A1 Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue |
03/31/2004 | EP1401442A1 S-omeprazole (esomeprazole inclusion complex with cyclodextrins |
03/31/2004 | EP1401435A1 Topical application of thiazolyl amides |
03/31/2004 | EP1401430A1 Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis |
03/31/2004 | EP1401423A1 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
03/31/2004 | EP1401420A2 Perturbed membrane-binding compounds |
03/31/2004 | EP1401409A2 Stable powder inhalation dosage formulation |
03/31/2004 | EP1401406A2 Delivery of a bioactive material |
03/31/2004 | EP1401405A1 Oral pharmaceutical compositions with improved bioavailability |
03/31/2004 | EP1401404A2 Method of encapsulating an active substance |
03/31/2004 | EP1401402A2 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin |
03/31/2004 | EP1401400A1 Porous matrix comprising cross-linked particles |
03/31/2004 | EP1401399A2 Pharmaceutical compositions containing polymer and drug assemblies |
03/31/2004 | EP1401398A1 PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF |
03/31/2004 | EP1401397A2 Pharmaceutical formulation having a masked taste and method for the production thereof |
03/31/2004 | EP1401396A2 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
03/31/2004 | EP1401377A2 Methods for treating cancer |
03/31/2004 | EP1401376A2 Colloidal metal compositions and methods |
03/31/2004 | EP1401374A1 A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same |
03/31/2004 | EP1401294A1 Method for manufacturing of free-flowing powder containing water-dispersible sterols |
03/31/2004 | EP1401290A2 Composition for regulating animal growth, method of manufacture and use thereof |
03/31/2004 | EP1305010B1 Dosage forms for treatment of oral mycoses |
03/31/2004 | EP1282393A4 External application for enhancing the skin permeability of the active components therein |
03/31/2004 | EP1250156A4 Method for nucleic acid transfection of cells |
03/31/2004 | EP1230338A4 Continuous-flow method for preparing microparticles |
03/31/2004 | EP1220685B1 Pharmaceutical compositions of fibrinolytic agent |
03/31/2004 | EP1218026B1 Preparation of a medicament to enhance healing of the sternum after sternotomy |
03/31/2004 | EP1171132B1 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol |
03/31/2004 | EP1165053B1 Fast-dispersing dosage forms containing fish gelatin |
03/31/2004 | EP1124543A4 Controlled release formulation for water soluble drugs |
03/31/2004 | EP1109526B1 Improved stability for injection solutions |
03/31/2004 | EP1073438B1 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDINE)-5H-BENZO (5,6) CYCLOHEPTA (1,2-b) PYRIDINE ORAL COMPOSITIONS |
03/31/2004 | EP1053020B1 Absorbable microparticles |
03/31/2004 | EP1012256B1 Recombinant fusion proteins based on ribosome-inactivating proteins of european mistletoe viscum album |
03/31/2004 | EP0975367B1 Improved delivery of drugs to mucosal surfaces |
03/31/2004 | EP0873130B1 Compositions comprising pvp having an average molecular weight in the range of 7.000 to 12.000 daltons |
03/31/2004 | EP0858343B1 Continuous low-dose cytokine infusion therapy |
03/31/2004 | EP0858323B1 Process to manufacture implants containing leuprolide |
03/31/2004 | EP0809498B1 Pharmaceuitical composition for topical application containing acyclovir and hydrocortisone |